Recently, Beijing Youngen Biotech Co., Ltd., an investee company of Hotgen Biotech, has seen four invention patent applications for its self-developed oligonucleotide drug candidates targeting metabolic diseases published by the China National Intellectual Property Administration (CNIPA). Publication numbers: CN121628900A, CN121825967A, CN121718537A, CN121628898A.
The published patents cover well-validated core metabolic targets supported by human genetic evidence, including PCSK9, LPA, ANGPTL3 and AGT. This milestone demonstrates that Youngen has built full-chain independent intellectual property rights spanning molecular sequences, chemical modifications and clinical indications in lipid metabolism disorders and blood pressure regulation. The comprehensive patent portfolio establishes solid barriers for the further advancement of its siRNA pipeline for chronic metabolic diseases.
Chronic metabolic disorders such as hyperlipidemia, hypertension and metabolic syndrome affect a large patient population requiring lifelong management. Conventional therapies have notable limitations and unmet clinical needs. Compared with monoclonal antibodies and small-molecule drugs, oligonucleotide drugs feature defined targets, high specificity and durable therapeutic effects. They help improve patient compliance and reduce frequent medication administration, have demonstrated tremendous advantages for chronic disease treatment. The vast unmet clinical demand makes metabolic disorders a high-ceiling blue-ocean market for siRNA therapeutics.
In clinical practice, patients with chronic metabolic diseases frequently suffer from comorbidities and overlapping health risks. Large groups of patients live with combined conditions such as hyperlipidemia complicated by hypertension and mixed hyperlipidemia. Traditional single-target drugs cannot simultaneously address multiple metabolic abnormalities, and long-term combined oral medication suffers from poor patient adherence. Real-world studies indicate that coordinated management of multiple metabolic disorders effectively prevents cardiovascular events and significantly lowers morbidity and mortality of cardio-cerebrovascular diseases.
With deep insights into real clinical demands, Youngen strategically develops innovative dual-target siRNA therapeutics based on its mature single-target pipelines. Leveraging proprietary chemical modification and GalNAc delivery platforms, the company enables simultaneous inhibition of two target genes. A single injection can coordinately regulate multiple cardiovascular metabolic pathways, tackling core therapeutic challenges of complex metabolic syndrome and building differentiated competitive advantages for its pipeline.
Breakthrough innovations in extrahepatic delivery technology and comprehensive chronic disease pipeline layout are two key benchmarks to evaluate core competitiveness and market positioning among oligonucleotide therapeutics developers. Adhering to differentiated innovation and focusing on unmet clinical needs, Youngen will advance both intrahepatic and extrahepatic technology platforms to expand the indication landscape of oligonucleotide drugs. The company aims to deliver long-acting, convenient novel treatment options for patients with metabolic diseases and inherited cardiovascular disorders.
Beijing Youngen Biotech Co., Ltd. is a high-tech biotech enterprise dedicated to the research, development and translation of innovative gene therapy medicines. Centered on disease mechanism research and novel drug discovery, the company has advanced multiple oligonucleotide drug pipelines with promising breakthrough progress. Supported by its pioneering delivery technology, Youngen Biotech vigorously develops innovative oligonucleotide therapies to address unmet clinical needs
